Silicon Valley, 03/28/2018 – Mitre Medical Corp. announces completion of the feasibility phase of the Study of the Mitral Touch System for the Reduction of Mitral Valve Regurgitation (the EnraptMR Trial). Treatment with the Mitral Touch implant has demonstrated safety and technical success including durability of MR reduction at 30 days.
“Validation of durable MR reduction on the beating hearts of these challenging patients is a real milestone for us at an interesting time.” says John MacMahon, CEO of Mitre Medical Corp. “We are fortunate that the structural heart space continues to be extremely active with two deals announced in the past three months – Edwards Lifesciences (Nasdaq:EW) in their acquisition of Harpoon Medical and Boston Scientific’s (Nasdaq: BSX) investment in Millipede.”
Echo Core Lab Director, Dr. Nina Wunderlich of the Cardiovascular Center Darmstadt stated, “There are definite acute benefits of normal anatomical restoration of the annulus in these patients.”
All patients were treated at Vilnius University Hospital Santaros Klinikos, Cardiac Surgery Center in Vilnius, Lithuania. The patients were treated by cardiac surgeons Kestutis Rucinskas, MD, PhD and Gintaras Kalinauskas, MD.
The Mitral Touch device is currently not approved by the FDA and is not CE marked.
About Mitre Medical Corp.
Mitre Medical Corp. is a medical device company with headquarters in Silicon Valley. The focus of the company is the development of innovative solutions to treat structural heart disease.